There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Galmed Pharmaceuticals (NASDAQ:GLMD) and Mesoblast Ltd (NASDAQ:MESO) with bullish sentiments.
Galmed Pharmaceuticals (GLMD)
In a report released today, Elemer Piros from Cantor Fitzgerald maintained a Buy rating on Galmed Pharmaceuticals, with a price target of $59. The company’s shares opened today at $13.77.
Piros noted:
“We rate Galmed Pharmaceuticals Overweight. The company recently completed a Phase 2b study in NASH that achieved NASH resolution without worsening of fibrosis. Valuation Summary The sum of the risk-adjusted NPV yields an after-tax (21%), discounted (15%) value of over $1.2 billion (~$54/share), in our estimation. By adding an estimated $91 million (~$4/share) of YE cash, the total value is ~$1.3 billion in our calculation, or $59/share, our 12-month PT.”
According to TipRanks.com, Piros is a 1-star analyst with an average return of -1.5% and a 46.4% success rate. Piros covers the Healthcare sector, focusing on stocks such as Spring Bank Pharmaceuticals Inc, Strongbridge Biopharma Plc, and Global Blood Therapeutics.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Galmed Pharmaceuticals with a $36.60 average price target.
See today’s analyst top recommended stocks >>
Mesoblast Ltd (MESO)
In a report released today, Jason McCarthy from Maxim Group maintained a Buy rating on Mesoblast Ltd, with a price target of $16. The company’s shares opened today at $7.75.
McCarthy commented:
“Mesoblast announced that the results of its P2b study evaluating MPC-150- IM (allogeneic cell therapy) in end-stage heart failure patients implanted with a left ventricular assist device (LVAD) has been selected as a late- breaking presentation at the 2018 in Chicago. The presentation (on Nov. 11) is entitled ‘Intramyocardial Impact on Myocardial Recovery and Morbidity.’.”
According to TipRanks.com, McCarthy is a 5-star analyst with an average return of 21.9% and a 53.3% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as SELLAS Life Sciences Group Inc, ContraVir Pharmaceuticals Inc, and Sonoma Pharmaceuticals Inc.
Mesoblast Ltd has an analyst consensus of Strong Buy, with a price target consensus of $18, a 132.3% upside from current levels. In a report issued on September 18, H.C. Wainwright also maintained a Buy rating on the stock with a $17 price target.
.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
